May 18, 2016
Wilson Therapeutics announces that the ongoing Phase II study has been fully enrolled
Media
May 17, 2016
Strongbridge Biopharma plc Reports First Quarter 2016 Financial Results
May 12, 2016
HealthCap’s 35th IPO as HealthCap VI company Wilson Therapeutics completes listing on Nasdaq OMX Stockholm
May 12, 2016
Targovax ASA: Interim report first quarter 2016
May 09, 2016
Nordic Nanovector announces an open Investigational New Drug application for new clinical study of Betalutin® in diffuse large B-cell lymphoma
May 05, 2016
Strongbridge Biopharma plc Announces Presentation at Bio€quity Europe 2016
May 04, 2016
Nordic Nanovector announces first patient enrolled in Arm 3 of expanded Phase 1/2 study of Betalutin® in NHL patients
May 03, 2016
Q1 2016 General Market Overview
April 29, 2016
WILSON THERAPEUTICS ANNOUNCES INITIAL PUBLIC OFFERING ON NASDAQ STOCKHOLM
April 21, 2016
Interim Report January-March 2016